ECONOMIC EVALUATION OF SUNITINIB, SORAFENIB, BEVACIZUMAB/INTERFERON ALPHA AND TEMSIROLIMUS IN FIRST LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ISRAEL

被引：1
|
作者：
Greenberg, D. [1 ]
机构：
[1] Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)73269-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A42 / A42
页数：1
相关论文
共 50 条
  • [1] Sunitinib, Sorafenib, Temsirolimus or Bevacizumab in the Treatment of Metastatic Renal Cell Carcinoma: A Review of Health Economic Evaluations
    Norum, J.
    Nieder, C.
    Kondo, M.
    JOURNAL OF CHEMOTHERAPY, 2010, 22 (02) : 75 - 82
  • [2] Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon-alfa or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): An indirect comparison
    Benedict, A.
    Charbonneau, C.
    Hidi, J.
    Kim, S. T.
    Negrier, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Sunitinib, sorafenib, temsirolimus, or bevacizumab in the treatment of metastatic renal cell carcinoma (RCC): A review of health economic evaluations
    Norum, J.
    Nieder, C.
    Kondo, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] ECONOMIC EVALUATION OF SUNITINIB FIRST-LINE FOR METASTATIC RENAL CELL CARCINOMA VERSUS SORAFENIB, TEMSIROLIMUS AND BEVACIZUMAB plus INTERFERON-ALFA IN THE SWEDISH HEALTH SERVICE SETTING
    Munir, U.
    Benedict, A.
    Borgman, B.
    Sandin, R.
    Harmenberg, U.
    Ullen, A.
    Sandstrom, P.
    VALUE IN HEALTH, 2008, 11 (06) : A468 - A468
  • [5] Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
    Coon, J. Thompson
    Hoyle, M.
    Green, C.
    Liu, Z.
    Welch, K.
    Moxham, T.
    Stein, K.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 (02) : 1 - +
  • [6] Economic Evaluation of Everolimus versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma after Failure of First-Line Sunitinib
    Casciano, Roman
    Chulikavit, Maruit
    Di Lorenzo, Giuseppe
    Liu, Zhimei
    Baladi, Jean-Francois
    Wang, Xufang
    Robertson, Justin
    Garrison, Lou
    VALUE IN HEALTH, 2011, 14 (06) : 846 - 851
  • [7] Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma
    Remak, Edit
    Charbonneau, Claudie
    Negrier, Sylvie
    Kim, Sindy T.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3995 - 4000
  • [8] ECONOMIC EVALUATION OF SUNITINIB AS FIRST-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN COLOMBIA
    Prieto, V. A.
    Reyes, J. M.
    Lopez-Cabra, C.
    Diaz, J. A.
    Urrego-Novoa, J. R.
    VALUE IN HEALTH, 2016, 19 (03) : A149 - A149
  • [9] Economic evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma in Mexico
    Emilio, Mucino-Ortega
    Joaquin Federico, Mould-Quevedo
    GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (02): : 48 - 57
  • [10] COST EFFECTIVENESS ANALYSIS OF SUNITINIB, BEVACIZUMAB plus INTERFERON-ALFA AND TEMSIROLIMUS AS FIRST-LINE THERAPY OF METASTATIC RENAL CELL CARCINOMA IN SWEDEN
    Remak, E.
    Vioix, H.
    Sandin, R.
    Harmenberg, U.
    Ullen, A.
    Sandstrom, P.
    VALUE IN HEALTH, 2009, 12 (07) : A270 - A270
12345